[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363019-105":59,"doc-detail-363019-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ctdna-dynamics-and-recurrence-patterns-after-organ-sparing-trimodality-therapy-for-bladder-cancer","ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer","","Trimodality therapy (TMT) is a bladder-sparing approach for muscle-invasive bladder cancer (MIBC), but plasma circulating tumor DNA (ctDNA) associations with outcomes after TMT are not well defined. In this study, MIBC patients receiving TMT at participating centers underwent ctDNA evaluation at baseline and at regular intervals using the Signatera assay, alongside routine surveillance with imaging and cystoscopy. Associations between ctDNA status and clinical disease status were assessed.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ctdna-dynamics-and-recurrence-patterns-after-organ-sparing-trimodality-therapy-for-bladder-cancer/363019/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ctdna-dynamics-and-recurrence-patterns-after-organ-sparing-trimodality-therapy-for-bladder-cancer/363019.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical question does the study address about ctDNA after TMT?","Question",{"text":113,"@type":114},"It evaluates how plasma ctDNA status relates to clinical outcomes in patients treated with trimodality therapy for MIBC, where the association was previously poorly characterized.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was ctDNA measured in the study?",{"text":118,"@type":114},"Patients had ctDNA testing at baseline and at regular intervals after TMT using the commercially available Signatera assay.",{"name":120,"@type":111,"acceptedAnswer":121},"What recurrence patterns were linked to detectable ctDNA after chemoradiotherapy?",{"text":122,"@type":114},"Detectable ctDNA following chemoradiotherapy was strongly correlated with metastatic recurrence, while no patients with isolated muscle-invasive or non–muscle invasive recurrence showed detectable ctDNA prior to recurrence.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363019,1790212003,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ctDNA Dynamics and Recurrence Patterns after  \nOrgan-Sparing Trimodality Therapy for Bladder Cancer  \nIlana B. Epstein1, Adetolani Odogiyon2, Stephanie Berg1, Yukako Otani2, Charlene Mantia1, Isabella R. Pompa2, Matthew Mossanen3, Joshua Wan2, Anurag Saraf2,4, Mark Preston3, Arvind Ravi1, Filipe Carvalho3, Cameron Herberts5, Adam ElNaggar5, Timothy Clinton3, Daniel Roberts1,  \nLuke Peng2,4, Bradley McGregor1, Joaquim Bellmunt1, Sophia C. Kamran2, Jacob E. Berchuck6, Jason A. Efstathiou2, David T. Miyamoto2, and Kent W. Mouw2,4  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Trimodality therapy (TMT) is a bladder-sparing treatment approach for patients with muscle-invasive bladder cancer (MIBC) . Although plasma circulating tumor DNA (ctDNA) is correlated with treatment response and outcomes following cystectomy for MIBC, the association of plasma ctDNA with clinical outcomes in patients treated with TMT is poorly characterized.\u003Cbr>Experimental Design: Patients with MIBC who received TMTat Dana-Farber/Brigham and Women’s Cancer Center or Massachusetts General Hospital were consented to a research protocol and underwent ctDNA evaluation at baseline and at regular intervals following TMT using the commercially available Signatera assay. All patients also underwent routine post-TMT surveillance including cross-sectional imaging and cystoscopic evaluation. The association between ctDNA status and clinical disease status was assessed.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: Eighty-four patients had at least one ctDNA result. Fifty-nine patients had a ctDNA test performed prior to chemoradiotherapy (CRT), and 19 (32%) had detectable ctDNA. Forty-six patients had paired pre- and post-CRT ctDNA results available: nearly all (29/31, 94%) patients with undetectable ctDNA prior to CRT also had undetectable ctDNA at the first post-CRT assessment, whereas 11 of 15 (73%) patients with detectable ctDNA prior to CRT converted to undetectable ctDNA following CRT. Sixteen (19%) patients developed metastatic disease, and detectable ctDNA following CRT was strongly correlated with metastatic recurrence (P \u003C 0.0001). Conversely, no patients with an isolated muscle-invasive (n ¼ 5) or non–muscle invasive (n ¼ 7) bladder recurrence had a post-TMT test demonstrating detectable ctDNA prior to recurrence.\u003Cbr>Conclusions: ctDNA detectability is strongly correlated with metastatic but not local disease recurrence in patients with MIBC following TMT. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nBladder cancer is a significant global health problem, accounting for more than 600,000 new cancer diagnoses and 200,000 deaths annually (1) . Approximately one in four patients with bladder cancer presents with muscle-invasive bladder cancer (MIBC), an aggressive but potentially curable disease state. Two curative-intent treatment approaches for MIBC are supported by","cbCaiggVMPEvCUgz","https://ap.wps.com/l/cbCaiggVMPEvCUgz","pdf",1086461,"English","# Purpose\n# Experimental Design\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What clinical question does the study address about ctDNA after TMT?\",\"answer\":\"It evaluates how plasma ctDNA status relates to clinical outcomes in patients treated with trimodality therapy for MIBC, where the association was previously poorly characterized.\"},{\"question\":\"How was ctDNA measured in the study?\",\"answer\":\"Patients had ctDNA testing at baseline and at regular intervals after TMT using the commercially available Signatera assay.\"},{\"question\":\"What recurrence patterns were linked to detectable ctDNA after chemoradiotherapy?\",\"answer\":\"Detectable ctDNA following chemoradiotherapy was strongly correlated with metastatic recurrence, while no patients with isolated muscle-invasive or non–muscle invasive recurrence showed detectable ctDNA prior to recurrence.\"}]","ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer | PDF",1790149673,15,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35426515c99dd699bd79b80757987858.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd486fdf1ccccb0cd2821080ae528c4f.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e17e5aab7374a1a7a26aa9e05e59a2d.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/418ed417340d317815b4d24100125f06.webp",980,1311]